Status | Study |
Completed |
Study Name: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Condition: Measles Mumps Rubella Va Date: 2013-11-08 Interventions: Biological: MMR Bio-Manguinhos |
Completed |
Study Name: Retrospective Clinical Outcome of Parotid Tumor Surgery Condition: Parotid Tumors Postoperative Complications Date: 2013-10-27 |
Completed |
Study Name: Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) Condition: Mumps Rubella Measles Date: 2013-06-07 Interventions: Biological: MMR (Mumps, Measles and Rubella) MMR (Mumps, Measles and Rubella) |
Completed |
Study Name: Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Condition: Measles Mumps Rubella Date: 2013-01-21 Interventions: Biological: MMR Vaccine Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKlin |
Withdrawn |
Study Name: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines Condition: Mumps Rubella Measles Va Date: 2012-11-28 Interventions: Biological: Priorix-Tetra™ |
Completed |
Study Name: A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children Condition: The Study Focused on the Safety of Attenuated Mumps Vaccine (Human Diploid Cell) Against Mumps in Chinese Adults, Children and Infants. Date: 2012-10-22 Interventions: Biological: 3.50±0.25logCCID50/ml |
Completed |
Study Name: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Condition: Measles Mumps Rubella Date: 2012-09-06 Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209 |
Completed |
Study Name: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Condition: Rubella Mumps Measles Date: 2012-06-14 Interventions: Biological: Priorix® Sing |
Completed |
Study Name: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Condition: Measles Mumps Rubella Va Date: 2012-02-16 Interventions: Biological: MMRV (AMP) Measles |
Completed |
Study Name: The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Condition: Parotid Tumor Date: 2011-08-10 Interventions: Procedure: ADM 29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation |